The pandemic has faded away from our rear-view mirrors. But that was just the warm-up: now we’re driving headlong into a world facing existential pressures like never before. Companies are already responding in significant ways – whether cost-cutting profit drives (eg Novartis) or rewriting many of the conventional rules (eg Roche). And that’s just the present.
Whenever you write a business plan, you will have a vision of the future in your mind. But how often do you spend working on that vision? This webinar provides a unique opportunity to dream, to project and to predict.
Over the coming days and weeks, you’ll undoubtedly encounter many 2023 predictions. Most, to be frank, will be tepid. They’ll be safe and unimaginative, describing things we already know – such as the need for shorter-form content, the omnichannel rep or the continued malaise in capital markets. Well, duh.
Whereas, if you saw Paul’s 2021 or 2022 Predictions, you’ll know this will be an raw, audacious session, deliberately designed not to be ‘right’ but to get our brains racing at the bigger possibilities that lie ahead. Which pharma company will acquire a non-pharma company? Which industry that we rely on today will walk off a cliff tomorrow? What new technologies are poised to have a profound impact?
These are the bigger questions we’ll be answering on January 4, as we dust ourselves down for the biggest, bravest year in biopharma yet. Join us!
